Pharmacokinetics Of Apixaban In Patients Undergoing Pancreaticoduodenectomy

Study Overview

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of the duodenum.

This study will examine apixaban pharmacokinetic exposure (AUC(0-24)) and maximum concentration (Cmax) when administered as a single oral dose in patients who have undergone pancreaticoduodenectomy (PD) compared to historical controls. This is a phase one, single dose pharmacokinetic study in stable patients who have undergone pancreaticoduodenectomy. Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. This study aims to compare the pharmacokinetics and absorption of oral apixaban in patients who have undergone pancreaticoduodenectomy to that of apixaban in historical controls.

Pancreas Cancer
DVT
Pulmonary Embolism

DRUG: Apixaban

19D.811

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2019-12-06	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2021-12-06
First Submitted that Met QC Criteria 2019-12-06	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2021-12-23
First Posted (ACTUAL) 2019-12-10	Results First Posted N/A	Last Verified 2021-12

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Apixaban dosing Subjects to receive single dose of apixaban	DRUG: Apixaban Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Apixaban dosing

Subjects to receive single dose of apixaban

DRUG: Apixaban

Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban

Primary Outcome Measures	Measure Description	Time Frame
Serum Apixaban Level	Serum apixaban PK level	0-24 hours

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Be a male or female between ages 18-65 (inclusive) at the screening visit
May have a history of pharmacologically well-controlled hypertension or non-insulin dependent diabetes
Have a body mass index (BMI) ≥ 19 and ≤ 33 (inclusive)
BMI = (weight (kg))/(height (m2))
Have a history of pancreaticoduodenectomy
If female, subject can be of childbearing potential and must demonstrate a urine β-hCG level consistent with the non-gravid state at the screening visit and agree to use (and/or have their partner use) an acceptable method of birth control beginning at the screening visit throughout the trial (including washout intervals between treatment periods) and until 2 weeks after the last dose of trial drug in the last treatment period. Acceptable methods of birth control: intrauterine device ("IUD" with or without local hormone release, oral contraceptive pills, diaphragm, cervical cap, spermicides, contraceptive sponge, and /or condoms). Abstinence is an alternative life style and subjects practicing abstinence may be included in the trial.
Can be of non-childbearing potential which is defined as: a female who is postmenopausal without menses for at least 1 year and an FSH value in the postmenopausal range upon screening evaluation and/or a female who is status post hysterectomy, oophorectomy or tubal ligation.
Have serum creatinine level < 1.5 mg/dL
Have a prothrombin time (PT) and activated partial thromboplastin time (PTT) level below the upper limit of normal
Have platelet count within normal limits
Be willing to refrain from the use of anticoagulants and antiplatelet medications including aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) during the entire period of study participation
Be willing to comply with trial restrictions

Has a history of clinically significant medical condition that based upon the judgment of the investigator makes participation inappropriate
Has a history of a major bleeding event (defined as: (i) symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or (ii) a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of two or more units of whole blood or red cells) within 6 months prior to screening visit
Has had major surgery within 6 months prior to screening visit
Is actively taking any the following list of medications/supplements and cannot hold these medications for <5 half-lives prior to the study:
CYP3A4 Moderate/Strong Inhibitors:

Has a history of illicit drug abuse within six months prior to screening visit
Is an active smoker (last exposure <2 weeks prior to study screening)
Pregnant or lactating
Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce]) per day and cannot refrain from alcohol for the duration of the trial
Has a history of significant multiple and/or severe allergies (e.g. food, drug), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
Has known anaphylactic or severe systemic reactions to any components of apixaban or contraindication to the administration of apixaban
Has moderate or severe hepatic disease or other clinically relevant bleeding risk
Use of any drugs or products which at the discretion of the investigator would increase bleeding risk
Is considered inappropriate for participation by the investigator for any reason

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Walter K Kraft, MD, Thomas Jefferson University

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record